Co-Diagnostics shows a rounded $0.45 quote and a displayed gain of 74.45% in the latest supplied Penny Gems after-hours chart snapshot for November 9. Its India tuberculosis plans, November 10 financial update and convertible financing provide concrete business developments to examine alongside that move.
The after-hours snapshot differs from the regular-session close
The supplied intraday chart and key-data screen show the $0.45 rounded quote and 74.45% displayed gain. These are snapshot readings, not a claim that CODX rose 74.45% during the after-hours session alone. The screenshots were identified as after-hours views; their exact capture time and time zone have not been independently verified.
An earlier gainers-list image, also included below, showed a rounded $0.60 quote and a 131.50% gain. The two sets record different readings and should not be treated as simultaneous quotations.
For regular-session context, Finviz labels the November 9 last close at a rounded $0.32, up 24.22%, timestamped 3:59 p.m. Eastern. MarketBeat labels the matching rounded price and percentage as the 4 p.m. Eastern closing price. Both services list extended-hours quotations separately.
The company has published developments relevant to its regulatory opportunity, upcoming results and financing. None of the sources reviewed establishes a new November 9 company announcement as the cause of the stock's rise.
India offers an opportunity with regulatory conditions
In its October 27 announcement, Co-Diagnostics said its Indian joint venture, CoSara Diagnostics, had completed a clinical study and regulatory submission for its point-of-care tuberculosis test. The study assessed 676 clinical samples, including 233 paired with MGIT testing for the reported comparison. Management expected Indian regulatory clearance during the fourth quarter and commercial sales before year-end, subject to authorization.
These are meaningful development steps, but the distinction between a completed submission and a completed approval matters. A regulator can request more information, change the timetable or decline authorization. A planned sales launch also leaves execution questions: whether customers adopt the product, whether distribution works and how much revenue the product ultimately generates. These are questions to follow, rather than outcomes established by the announcement.
A November 5 company update described participation in three international tuberculosis events as CoSara prepared for its anticipated India launch. That provides commercial-development context. Conference participation does not itself establish a purchase order or regulatory decision. The release also stated that the CoSara PCR Pro instrument and associated tests had not been cleared or approved by the U.S. Food and Drug Administration and were unavailable for sale in the United States.
November 10 earnings provide a financial checkpoint
Co-Diagnostics said it would release third-quarter results after the market closes on November 10, followed by a webcast at 4:30 p.m. Eastern. The company moved that release forward from November 12 in an announcement dated November 5.
The financial report offers a way to compare development plans with the resources supporting them. Relevant items include available cash, operating cash use, existing revenue and management's discussion of launch expenses. A regulatory timetable can attract attention well before a product makes a meaningful contribution to sales. Reading those operating and financial measures together gives a fuller picture than a percentage-gainers screen alone.
Financing adds another part of the story
A legal opinion filed with the SEC identifies a registration covering up to 39.59 million common shares for resale. It describes shares issued or issuable under an October 9 loan agreement, including convertible-note shares and 600,000 commitment shares.
Registration is not confirmation that every registered share has already entered the market. The distinction matters because potential share issuance, actual outstanding shares and completed resales measure different things. Convertible financing can supply capital while creating dilution exposure if additional shares are issued. Assessing that exposure requires the financing terms and subsequent filings, rather than treating the maximum registration amount as an immediate sale.
For readers following CODX, the next useful evidence is therefore concrete: the financial release, any subsequent regulatory decision and updates showing whether commercial preparations become sales. The snapshot records attention at one moment; it does not settle those business questions.
This article is general market reporting, not a personal investment recommendation. Small-company stocks can be volatile, and displayed quotations may change rapidly.
